Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID 2018038
Author(s) Petersen, Svea; Hussner, Janine; Reske, Thomas; Grabow, Niels; Senz, Volkmar; Begunk, Robert; Arbeiter, Daniela; Kroemer, Heyo K; Schmitz, Klaus-Peter; Meyer zu Schwabedissen, Henriette E; Sternberg, Katrin
Author(s) at UniBasel Meyer zu Schwabedissen, Henriette
Hussner, Janine
Year 2014
Title In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release
Journal Journal of materials science. Materials in medicine
Volume 24
Number 11
Pages / Article-Number 2589-600

Within the context of novel stent designs we developed a dual drug-eluting stent (DDES) with an abluminally focussed release of the potent anti-proliferative drug sirolimus and a luminally focussed release of atorvastatin with stabilizing effect on atherosclerotic deposits and stimulating impact on endothelial function, both from biodegradable poly(L-lactide)-based stent coatings. With this concept we aim at simultaneous inhibition of in-stent restenosis as a result of disproportionally increased smooth muscle cell proliferation and migration as well as thrombosis due to failed or incomplete endothelialisation. The especially adapted spray-coating processes allowed the formation of smooth form-fit polymer coatings at the abluminal and luminal side with 70 % respectively 90 % of the drug/polymer solution being deposited at the intended stent surface. The impacts of tempering, sterilization, and layer composition on drug release are thoroughly discussed making use of a semi-empirical model. While tempering at 80 įC seems to be necessary for the achievement of adequate and sustained drug release, the coating sequence for DDES should be rather abluminal-luminal than luminal-abluminal, as reduction of the amount of sirolimus eluted luminally could then potentially minimize the provocation of endothelial dysfunction. In vitro proliferation and viability assays with smooth muscle and endothelial cells underline the high potential of the developed DDES.

Publisher Kluwer Academic Press
ISSN/ISBN 0957-4530
Full Text on edoc No
Digital Object Identifier DOI 10.1007/s10856-013-5001-7
PubMed ID
ISI-Number WOS:000326049900011
Document type (ISI) Journal Article

MCSS v5.8 PRO. 0.357 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |